Iranian Journal of Neurology 2017. 16(1):1-6.

Comparison of the effects of low dose interferon and high dose interferon on reduction of the number and size of plaques in patients with Multiple Sclerosis: A historical cohort
Payam Khomand, Ghobad Moradi, Behrooz Ahsan, Setareh Abtahi

Abstract


Background: This study was performed to compare the effects of low dose interferon beta-1 (IFN-β-1) (CinnoVex, 30 mcg) and high dose
IFN-β-1 (REBIF, 44 mcg) on the reduction of the number and size of plaques in magnetic resonance imaging (MRI) in patients with multiple sclerosis (MS).

Methods: This historical cohort study, which was performed in 2014 in Sanandaj (western part of Iran). 43 MS patients in two groups were investigated. The first group, which included 19 patients, was treated using high dose IFN (44 mcg) and the second group, which was consisted of 24 patients, was treated using low dose IFN (30 mcg). Patients’ data were collected and analyzed by the Stata version 11 software; the analyses were performed using statistical t-test, chi-square test, Fisher test, and logistic regression.

Results: Both drugs were effective in controlling active demyelinating plaque and in preventing plaque activation (P = 0.633). The impact of both drugs in the reduction of the number and size of plaques was evaluated. Based on the results of the MRI, high dose IFN therapy was more effective than the low dose IFN drugs and had a better performance in terms of reducing the number of plaques and in stop-and-recovery (P = 0.039), as well as in reducing the plaque size (P = 0.050).

Conclusion: The high dose IFN therapy was more effective than the low dose IFN therapy in reducing the number and size of brain plaques in patients with relapsing-remitting MS (RRMS).


Keywords


Multiple Sclerosis; High Dose Interferon; Low Dose Interferon; Magnetic Resonance Imaging

Full Text:

PDF

References


Niedziela N, Adamczyk-Sowa M, Pierzchala K. Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci 2014; 124(5): 322-30.

Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014; 13(4-5): 518-24.

Tsang BK, Macdonell R. Multiple sclerosis- diagnosis, management and prognosis. Aust Fam Physician 2011;40(12): 948-55.

Filippi M, Rocca MA, Barkhof F, Bruck W, Chen JT, Comi G, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11(4): 349-60

Pittock SJ, Noseworthy JH, Rodriguez M.MRI findings in benign multiple sclerosis are variable. J Neurol 2007; 254(4):539-41.

Li T, Xiao H, Li S, Du X, Zhou J. Multiple sclerosis: clinical features and MRI findings in Northern China. Eur J Med Res 2014; 19: 20.

Mahurkar S, Suppiah V, O'Doherty C.Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev 2014;13(2): 178-86.

Murdoch D, Lyseng-Williamson KA.Subcutaneous recombinant interferon- beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. Drugs 2005; 65(9): 1295-312.

Sanford M, Lyseng-Williamson KA.Subcutaneous recombinant interferon- beta-1a (Rebif(R)): a review of its use in the treatment of relapsing multiple sclerosis. Drugs 2011; 71(14): 1865-91.

Devonshire VA, Verdun di Cantogno E.Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis. Ther Deliv 2011; 2(11): 1455-65.

Vallittu AM, Halminen M, Peltoniemi J,Ilonen J, Julkunen I, Salmi A, et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a- treated MS patients. Neurology 2002;58(12): 1786-90.

Martina IS, van Doorn PA, Schmitz PI, Meulstee J, van der Meche FG. Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999; 66(2):197-201.

Etemadifar M, Maghzi AH, Hoseinzadeh A. Comparing side effects of CinnoVex with Avonex in relapsing remitting multiple sclerosis patients. J Isfahan Med Sch 2009; 27(93): 93-101. [In Persian].

Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, et al. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon beta-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurol 2011; 11: 125.

Mori F, Kusayanagi H, Buttari F, Centini B, Monteleone F, Nicoletti CG, et al. Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity de fi cits in multiple sclerosis. Funct Neurol 2012; 27(3): 163-8.

Lowery-Nordberg M, Eaton E, Gonzalez- Toledo E, Harris MK, Chalamidas K, McGee-Brown J, et al. The effects of high dose interferon-beta1a on plasma microparticles: correlation with MRI parameters. J Neuroinflammation 2011;8: 43.

Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009; 10(2): 291-309.

Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis:the EVIDENCE Study. Arch Neurol 2005; 62(5): 785-92.

Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56(11): 1505-13.

Oliver BJ, Kohli E, Kasper LH.Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci 2011; 302(1-2):96-105.

Prosperini L, Borriello G, De Giglio L, Leonardi L, Barletta V, Pozzilli C. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? BMC Neurol 2011; 11: 26


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.